KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Debt to Equity (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Debt to Equity data on record, last reported at -$1.11 in Q4 2025.

  • For Q4 2025, Debt to Equity fell 106.11% year-over-year to -$1.11; the TTM value through Dec 2025 reached -$1.11, down 106.11%, while the annual FY2025 figure was -$1.11, 106.11% down from the prior year.
  • Debt to Equity reached -$1.11 in Q4 2025 per AQST's latest filing, up from -$8.83 in the prior quarter.
  • Across five years, Debt to Equity topped out at -$0.26 in Q4 2023 and bottomed at -$8.83 in Q3 2025.
  • Average Debt to Equity over 5 years is -$0.97, with a median of -$0.55 recorded in 2024.
  • Peak YoY movement for Debt to Equity: soared 74.88% in 2021, then plummeted 1181.69% in 2025.
  • A 5-year view of Debt to Equity shows it stood at -$0.65 in 2021, then soared by 32.57% to -$0.44 in 2022, then surged by 41.23% to -$0.26 in 2023, then plummeted by 109.14% to -$0.54 in 2024, then plummeted by 106.11% to -$1.11 in 2025.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were -$1.11 in Q4 2025, -$8.83 in Q3 2025, and -$0.48 in Q2 2025.